Comparative Pharmacology
Head-to-head clinical analysis: BROVANA versus MAXAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROVANA versus MAXAIR.
BROVANA vs MAXAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BROVANA (arformoterol tartrate) is a long-acting beta2-adrenergic agonist (LABA). It stimulates intracellular adenyl cyclase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular cAMP.
15 mcg (2 mL) by nebulization twice daily, not to exceed 30 mcg/day.
2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.
None Documented
None Documented
Terminal elimination half-life: approximately 26 hours (range 22–30 hours) in healthy adults; prolonged in hepatic impairment (up to 50% increase).
3.5–4.0 hours; clinically, this supports dosing every 4–6 hours as needed.
Primarily renal (60% unchanged drug); remainder via biliary/fecal (approximately 20%) and metabolic transformation.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; fecal excretion is minimal (<5%).
Category C
Category C
Bronchodilator
Bronchodilator